Welcome to our dedicated page for Alx Oncology Holdings SEC filings (Ticker: ALXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ALX Oncology Holdings Inc. filings document a clinical-stage biotechnology issuer focused on cancer therapeutics and its Nasdaq-listed common stock. Recent 8-K reports furnish quarterly and annual financial results, corporate updates, clinical data releases for evorpacept and ALX2004, preliminary cash and investment information, and capital-structure disclosures tied to common stock and pre-funded warrant financing.
Proxy and governance filings describe board matters, executive compensation, equity awards, and shareholder voting items. Other material-event reports cover officer appointments, employment and compensatory arrangements, and amendments to the 2025 Inducement Equity Incentive Plan under Nasdaq inducement award rules.
ALX Oncology Holdings Inc reported that Chief Medical Officer Barbara Klencke received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $1.68 per share and expire on April 15, 2036.
One-fourth of the option shares vest on February 25, 2027, and the remaining shares vest in equal monthly installments of 1/48th thereafter. This is a compensation-related award rather than an open-market stock purchase or sale.
ALX Oncology Holdings Inc identified Jeff E. Knight, its Chief Dev & Operating Officer, as a reporting person in a Form 3 insider filing. The data provided shows no reported purchases, sales, gifts, tax withholdings, restructurings, or derivative exercises, and no holdings are detailed.
ALX Oncology Holdings Inc. appointed Jeff Knight as Chief Development and Operating Officer, effective April 13, 2026. Knight is a veteran biopharmaceutical executive with more than three decades of experience in clinical development, regulatory affairs, and operational leadership at companies including Crinetics, Poseida, Halozyme, Amgen, Onyx, and Genentech.
Under his employment offer letter, Knight will receive an annual base salary of $565,000 and be eligible for an annual target cash bonus equal to 40% of base salary. He will also receive a stock option to purchase 800,000 shares of ALX Oncology common stock under the 2025 Inducement Equity Incentive Plan, vesting 25% after one year and the remainder in equal monthly installments over the following three years, subject to continued service.
He has entered into the company’s standard change of control and severance and indemnification agreements. A related press release highlighting his role in supporting upcoming clinical milestones for evorpacept and ALX2004 was furnished as an exhibit.
ALX Oncology Holdings director and chief executive officer Jason Lettmann reported an open-market sale of 12,311 shares of common stock at $2.17 per share on March 19, 2026. According to the filing, the shares were sold to satisfy his tax obligations related to the vesting of performance-based restricted stock units. After this transaction, he directly holds 293,609 shares of ALX Oncology common stock.
ALX Oncology Holdings Inc. senior vice president of finance and chief accounting officer Shelly Pinto reported a small open-market sale of common stock. On March 19, 2026, she sold 903 shares at $2.17 per share. According to the footnote, the shares were sold to satisfy her tax obligations related to the vesting of performance-based restricted stock units, indicating a tax-driven, routine transaction rather than a discretionary portfolio move. After this sale, Pinto directly holds 86,805 shares of ALX Oncology common stock.
ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on cancer immunotherapies targeting the CD47 pathway and EGFR. It highlights evorpacept, a CD47 blocker with an inactive Fc domain designed to avoid blood toxicities seen in earlier CD47 drugs, and ALX2004, a novel EGFR-targeted antibody-drug conjugate.
Evorpacept has been studied in gastric, breast, lymphoma and multiple myeloma settings, often combined with antibodies such as trastuzumab, rituximab and zanidatamab. In gastric/GEJ cancer, adding evorpacept to standard HER2-directed therapy improved objective response rates and response duration, especially in tumors with high CD47 expression.
ALX2004, built with an in-house topoisomerase I payload and a matuzumab-derived antibody, showed strong preclinical tumor killing and bystander effect with encouraging non-human primate safety, and is now in a Phase 1 trial in EGFR-expressing solid tumors. As of June 30, 2025, non-affiliate common equity market value was $18.0 million, and 131,608,278 common shares were outstanding as of March 2, 2026.
ALX Oncology Holdings Inc reported that Chief Medical Officer Barbara Klencke received a grant of stock options representing 700,000 shares of the company’s stock. This is recorded as a derivative security transaction categorized as a grant, award, or other acquisition.
According to the vesting terms, one-fourth of the shares subject to the option vest on February 25, 2027, and the remaining portion vests in equal monthly installments of 1/48th thereafter. Following this grant, she is shown as holding 700,000 stock options directly.
ALX Oncology Holdings Inc Chief Medical Officer Barbara Klencke filed an initial Form 3 reporting her equity interests in the company. She lists several stock option awards and common stock positions, reflecting both direct and indirect ownership.
The filing reports stock options over 40,400, 300,000 and 100,000 shares, plus 60,000 common shares held directly and another 60,000 common shares held indirectly by her spouse. Footnotes describe vesting schedules for the options, with installments beginning on February 21, 2025, September 17, 2025, January 31, 2026, June 30, 2026 and February 26, 2026.
ALX Oncology reported 2025 results showing lower expenses and a stronger balance sheet while advancing two key cancer programs. Research and development spending fell to $77.0M from $116.4M, and general and administrative costs declined to $23.9M from $26.1M.
GAAP net loss narrowed to $101.7M, or $1.90 per share, from $134.9M, or $2.58 per share. The company ended 2025 with $48.3M in cash, cash equivalents and investments, then raised $150M in a registered equity offering, yielding $140.4M in net proceeds.
Management expects this cash to fund operations through the first half of 2028, covering major milestones for lead CD47 inhibitor evorpacept and EGFR-targeted ADC ALX2004. Multiple clinical data readouts are planned between 2026 and mid-2027, including biomarker analyses and Phase 1 safety results.
ALX Oncology Holdings Inc. senior vice president and chief accounting officer Shelly Pinto reported an open-market sale of 565 shares of common stock at $2.27 per share. According to the disclosure, the shares were sold solely to cover tax obligations from vesting restricted stock units. After this transaction, Pinto holds 87,708 shares directly.